In line with our findings, recent clinical trials of SGLT-2 inhibitors in non-diabetic patients with chronic kidney disease or heart failure have also demonstrated divergent results regarding the metabolic effects in non-diabetic patients [46,47] meaning that the metabolic effects in non-diabetic patients are not as strong as in diabetic patients [48], although they had similar preserved cardiorenal protection. This evidence concerns the gene SLC5A2 and heart failure.